Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Socie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Gilleece, Maria H., Shimoni, Avichai, Labopin, Myriam, Robinson, Stephen, Beelen, Dietrich, Socié, Gerard, Unal, Ali, Ganser, Arnold, Vitek, Antonin, Sengeloev, Henrik, Yakoub-Agha, Ibrahim, Tholouli, Eleni, Polge, Emmanuelle, Mohty, Mohamad, Nagler, Arnon
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8116335/
https://ncbi.nlm.nih.gov/pubmed/33980810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00479-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars